Bayer
FDA approves Bayer haemophilia A drug Kovaltry
March 17, 2016Research and Development, Sales and Marketing Bayer, FDA, approval, drug, drug approval, haemophilia, haemophilia a, kovaltry, viii compound
Bayer (ETR:BAYN) has received approval from the US Food and Drug Administration (FDA) for Kovaltry (octocog alfa), an unmodified, full-length …
Bayer to collaborate on new treatments for tuberculosis with Universities of Dundee, Cape Town
March 8, 2016Manufacturing and Production, Research and Development Bayer, TB, tuberculosis, university of cape town, university of dundee
The pharmaceuticals division at German-based Bayer will collaborate with the renowned medicinal chemistry and biology departments at the Universities of …
Bayer names Werner Baumann new CEO
February 26, 2016Medical Communications Bayer
Werner Baumann will become the new chief executive of Bayer AG from May 1, the company has announced. The decision …
Europe approves Bayer haemophilia drug
February 22, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bayer, haemophilia a
Bayer has received approval from the European Commission for its haemophilia A drug Kovaltry (octocog alfa) in patients of all …
Investigation questions Xarelto trial data accuracy
February 4, 2016Medical Communications BMJ, Bayer, INR, Johnson & Johnson, New England Journal of Medicine, Rocket-AF, Xarelto, blood clotting, rivaroxaban
The ROCKET-AF trial, the pivotal trial of the top-selling anti-clotting drug Xarelto, could have been undermined by unreliable results from …
Bayer opens OTC drug plant in China
January 19, 2016Manufacturing and Production Bayer, China, OTC, TCM, Yunnan, over the counter, traditional Chinese medicine
Bayer has opened a new manufacturing plant to produce over-the-counter (OTC) drugs in China, as the German firm looks to …
Bayer and Baxalta in separate €1 billion-plus deals
January 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Ascensia diabetes care, Baxalta, Bayer, diabetes, panasonic, symphogen
Baxalta has signed a deal with Symphogen potentially worth as much as €1.4 billion, under which the companies will develop …
Bayer and Novartis to debut new data at ASH 2015
November 30, 2015Research and Development, Sales and Marketing American Society of Hematology, Bayer, Conference, Novartis, ash, clinical trials, haematology, oncology
Pharma firms will present clinical trial results for the pipeline drugs they are pinning their 2016 hopes for success on, …
Bayer takes on Actavis in ABPI code conduct breach
November 26, 2015Medical Communications, Sales and Marketing ABPI, Actavis, Bayer, PMCPA
The Prescription Medicines Code of Practice Authority (PMCPA) has ruled in favour of Bayer in a case brought against Actavis. …
NICE decision restricts Bayer’s Xofigo to select prostate cancer patients
November 19, 2015Research and Development, Sales and Marketing Bayer, NICE, prostate cancer
NICE has issued its Final Appraisal Determination (FAD) recommending Bayer’s Xofigo (radium-223 dichloride) for use on the NHS in England …
The ‘Pharmasaurus’ aims to evolve into a leader in the digital age
November 12, 2015Medical Communications, Research and Development Bayer, Roche, digital health, pharma
Pharma’s new-found willingness to embrace all aspects of the digital age, and use it both to its advantage and that …
Bayer, Regeneron’s Eylea gets additional EU indication
November 2, 2015Research and Development, Sales and Marketing Bayer, Eylea, Regeneron
The European Commission has granted a fifth indication to Bayer and Regeneron’s eye drug Eylea (aflibercept injection), which is now …
Bayer backs safety of Xarelto after real-world data study
September 2, 2015Research and Development Bayer, ESC, European Society of Cardiology, Xarelto, anticoagulants, atrial fibrillation, real-word evidence, rivaroxaban
Around 96 in every 100 people treated with Bayer’s anticoagulant Xarelto do not experience any major bleeding, related side effects …
Bayer’s complaint over ‘misleading’ Novartis eye drug claims upheld
August 14, 2015Medical Communications Bayer, Eylea, Lucentis, Novartis, PMCPA, code of conduct
The industry’s code of conduct regulator has ruled in favour of Bayer in a dispute claims made by Novartis when …
Working Life: Bayer UK & Ireland’s chief executive Alexander Moscho
July 6, 2015Manufacturing and Production, Research and Development, Sales and Marketing Alexander Moscho, Bayer
How did you find your way into your current role?I think it started when I was young and I was …
Latest content
